LSTA - LISATA THERAPEUTICS, INC.
IEX Last Trade
3.005
0 0%
Share volume: 1
Last Updated: Fri 27 Dec 2024 08:26:30 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.25%
PREVIOUS CLOSE
CHG
CHG%
$3.00
0.00
0.00%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
3.64%
1 Month
10.99%
3 Months
7.56%
6 Months
-9.80%
1 Year
9.75%
2 Year
24.07%
Key data
Stock price
$3.00
DAY RANGE
$3.00 - $3.00
52 WEEK RANGE
$2.66 - $3.83
52 WEEK CHANGE
$14.65
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
10/31/2024
Company detail
CEO: David J. Mazzo
Region: US
Website: caladrius.com
Employees: 30
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: caladrius.com
Employees: 30
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Caladrius Biosciences, Inc. focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia.
Recent news